Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
"Precursor B-Cell Lymphoblastic Leukemia-Lymphoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia.
| Descriptor ID |
D015452
|
| MeSH Number(s) |
C04.557.337.428.600.600 C15.604.515.560.600.600 C20.683.515.528.600.600
|
| Concept/Terms |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
- Precursor B Cell Lymphoblastic Leukemia Lymphoma
- Pre B-ALL
- Pre-B ALL
- Pre B ALL
- Precursor B-Cell Lymphoblastic Leukemia
- Precursor B Cell Lymphoblastic Leukemia
- Precursor B-Cell Lymphoblastic Lymphoma
- Precursor B Cell Lymphoblastic Lymphoma
- Leukemia, Pre-B-Cell
- Leukemia, Pre B Cell
- Leukemias, Pre-B-Cell
- Pre-B-Cell Leukemias
- Pre-B-Cell Leukemia
- Pre B Cell Leukemia
|
Below are MeSH descriptors whose meaning is more general than "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma".
Below are MeSH descriptors whose meaning is more specific than "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma".
This graph shows the total number of publications written about "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma" by people in this website by year, and whether "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 2 | 0 | 2 |
| 2010 | 2 | 0 | 2 |
| 2012 | 3 | 0 | 3 |
| 2013 | 1 | 0 | 1 |
| 2014 | 4 | 0 | 4 |
| 2015 | 2 | 0 | 2 |
| 2016 | 4 | 0 | 4 |
| 2017 | 2 | 0 | 2 |
| 2018 | 2 | 0 | 2 |
| 2019 | 5 | 0 | 5 |
| 2020 | 2 | 0 | 2 |
| 2021 | 4 | 0 | 4 |
| 2022 | 1 | 0 | 1 |
| 2023 | 2 | 0 | 2 |
| 2024 | 5 | 2 | 7 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Precursor B-Cell Lymphoblastic Leukemia-Lymphoma" by people in Profiles.
-
DNTT-mediated DNA damage response drives inotuzumab ozogamicin resistance in B-cell acute lymphoblastic leukemia. Blood. 2025 Mar 13; 145(11):1182-1194.
-
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL. Blood Adv. 2024 Dec 10; 8(23):6139-6147.
-
Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children. N Engl J Med. 2025 Feb 27; 392(9):875-891.
-
Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia. N Engl J Med. 2024 Dec 12; 391(23):2219-2230.
-
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL. J Clin Oncol. 2025 Feb 10; 43(5):558-566.
-
Impact of Age on Pharmacogenomics and Treatment Outcomes of B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2024 Oct 10; 42(29):3478-3490.
-
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults. N Engl J Med. 2024 Jul 25; 391(4):320-333.
-
Single-cell systems pharmacology identifies development-driven drug response and combination therapy in B cell acute lymphoblastic leukemia. Cancer Cell. 2024 Apr 08; 42(4):552-567.e6.
-
Developing Targeted Therapies for T Cell Acute Lymphoblastic Leukemia/Lymphoma. Curr Hematol Malig Rep. 2023 12; 18(6):217-225.
-
Sequencing antigen-targeting antibodies and cellular therapies in adults with relapsed/refractory B-cell acute lymphoblastic leukemia. Am J Hematol. 2023 04; 98(4):666-680.